mutations supplied the fact that, as described below, CLL therapy is predicated around the existence or absence of these mutations. The existing consensus is the fact, other than clonal mutations, subclonal mutations which has a variant allelic frequency ranging from 5 to 10% (and as a consequence beneath the threshold of detection by typical molec